CD274 and non-small cell lung carcinoma: In this study, patients with advanced NSCLC and PD‐L1 TPS ≥ 50% had greater benefits from ICI treatment compared to those with PD‐L1 TPS < 1% or PD‐L1 TPS1‐ 49%.